Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m).

Autor: Lucas SJE; School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK., Malein WL; Department of Anaesthesia, Ninewells Hospital, Dundee, UK., Thomas OD; Department of Anaesthesia, Royal Gwent Hospital, Aneurin Bevan University Health Board, Newport, UK., Ashdown KM; Occupational Performance Research Group, University of Chichester, Chichester, West Sussex, UK., Rue CA; Occupational Performance Research Group, University of Chichester, Chichester, West Sussex, UK., Joyce KE; School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK., Newman C; Royal Centre for Defence Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Cadigan P; Birmingham Medical Research Expeditionary Society, Birmingham, UK., Johnson B; Birmingham Medical Research Expeditionary Society, Birmingham, UK., Myers SD; Occupational Performance Research Group, University of Chichester, Chichester, West Sussex, UK., Myers FA; School of Biological Sciences, University of Portsmouth, Portsmouth, Hampshire, UK., Wright AD; School of Medicine, University of Birmingham, Birmingham, UK., Delamere J; School of Medicine, University of Birmingham, Birmingham, UK., Imray CHE; Department of Vascular Surgery, University Hospitals of Coventry and Warwickshire, Warwick Medical School, University of Warwick, Coventry, UK., Bradwell AR; School of Medicine, University of Birmingham, Birmingham, UK., Edsell M; Department of Anaesthesia, St George's University Hospitals NHS Foundation Trust, London, UK.
Jazyk: angličtina
Zdroj: BMJ open sport & exercise medicine [BMJ Open Sport Exerc Med] 2021 Jan 07; Vol. 7 (1), pp. e000982. Date of Electronic Publication: 2021 Jan 07 (Print Publication: 2021).
DOI: 10.1136/bmjsem-2020-000982
Abstrakt: Objective: Altitude-related and exercise-related elevations in blood pressure (BP) increase the likelihood of developing pulmonary hypertension and high-altitude illness during high-altitude sojourn. This study examined the antihypertensive effect and potential exercise benefit of the angiotensin II receptor antagonist losartan when taken at altitude.
Methods: Twenty participants, paired for age and ACE genotype status, completed a double-blinded, randomised study, where participants took either losartan (100 mg/day) or placebo for 21 days prior to arrival at 5035 m (Whymper Hut, Mt Chimborazo, Ecuador). Participants completed a maximal exercise test on a supine cycle ergometer at sea level (4 weeks prior) and within 48 hours of arrival to 5035 m (10-day ascent). Power output, beat-to-beat BP, oxygen saturation (SpO 2 ) and heart rate (HR) were recorded during exercise, with resting BP collected from daily medicals during ascent. Before and immediately following exercise at 5035 m, extravascular lung water prevalence was assessed with ultrasound (quantified via B-line count).
Results: At altitude, peak power was reduced relative to sea level (p<0.01) in both groups (losartan vs placebo: down 100±29 vs 91±28 W, p=0.55), while SpO 2 (70±6 vs 70±5%, p=0.96) and HR (146±21 vs 149±24 bpm, p=0.78) were similar between groups at peak power, as was the increase in systolic BP from rest to peak power (up 80±37 vs 69±33 mm Hg, p=0.56). Exercise increased B-line count (p<0.05), but not differently between groups (up 5±5 vs 8±10, p=0.44).
Conclusion: Losartan had no observable effect on resting or exercising BP, exercise-induced symptomology of pulmonary hypertension or performance at 5035 m.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)
Databáze: MEDLINE
Externí odkaz: